And finally, there is good news tonight about someone who got really creative with casual Fridays to bring joy and comfort where it is needed the most. Here's George. Three.At Galisano Children's Hospital in South Florida, Terry Aldrid isn't just a worker, she's a character. That's luau coming up. No, really, she is.That's her dressed as Sully from Monsters, Inc. manning the service desk. Thank you for calling. Answering calls.Hello. And checking in young patients ahead of surgery. For a lot of people, they ...

Financial Data and Key Metrics Changes - In Q2 2025, revenue increased by 11.9% to $1.65 billion, driven by adjusted admissions growth of 1.6% and net patient service revenue per adjusted admission growth of 10.2% [21] - Adjusted EBITDA grew 39% year over year to $170 million, with an adjusted EBITDA margin increase of 200 basis points to 10.3% [21] - Year-to-date adjusted EBITDA grew 23%, with margins expanding by 100 basis points compared to the prior year period [21] - Operating cash flow for Q2 was $117 million, with total cash at $541 million and total debt outstanding at $1.1 billion, resulting in a net leverage ratio of 2.7 times, improved from 3.0 times at the end of Q1 [22] Business Line Data and Key Metrics Changes - Admissions growth was strong at 6.6% year over year, with inpatient surgeries increasing by 9.2% in Q2, while outpatient surgeries declined by 3.8% [21][22] - Exchange admissions grew approximately 35% year over year, while commercial admissions (excluding exchange plans) and Medicaid admissions both increased by approximately 8% [21] Market Data and Key Metrics Changes - The company operates in eight growing mid-sized markets, which continue to drive demand due to an aging and increasingly complex patient population [5] - The company has seen nearly 40% growth in exchange admissions in 2025, although reimbursement rates for this population are less favorable compared to commercial rates [14] Company Strategy and Development Direction - The company is focused on expanding its outpatient services, with plans to open five urgent care centers and two imaging centers in 2025, complementing the 18 urgent care centers acquired earlier this year [9] - The IMPACT program aims to improve margins, performance, agility, and care transformation, with a focus on cost efficiency and operational agility [17][24] - The company is well-positioned to pursue strategic growth opportunities, particularly through joint ventures with academic partners in the acute care space [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining strong performance despite ongoing industry-wide payer denial headwinds, with a focus on operational workflow initiatives and strategic growth priorities [18][27] - The regulatory environment is being closely monitored, particularly regarding the Big Beautiful Bill (OBBA) and its potential impact on Medicaid funding [12][13] - Management anticipates a de minimis impact to earnings in 2026 and 2027, with the majority of financial effects occurring between 2028 and 2035 [14] Other Important Information - The company has reaffirmed its full-year 2025 financial guidance, indicating confidence in meeting its targets [18][25] - The company is now S-3 eligible following its one-year anniversary as a public company, allowing for potential capital raising opportunities in the future [25][26] Q&A Session Summary Question: Can you provide an update on managed care and the impact of terminated exchange contracts? - Management noted significant growth in exchange volume but mentioned that some plans were yielding poor rates, leading to the termination of one large plan [34] - Denial rates have increased, but the company remains focused on optimizing payer contracts to ensure appropriate compensation [35][36] Question: What is the outlook for the ambulatory strategy and its volume benefits? - The company is focused on growing the number of unique patients served in each market, with a current average of close to ten ambulatory access points per hospital [40] - Approximately 45% of patients from newly acquired urgent care centers were new to the company, indicating strong potential for follow-up care and additional services [42] Question: How is inpatient surgical growth performing and what categories are driving this? - Inpatient surgeries have been strong, particularly in orthopedics and cardiology, aligning with the company's service line rationalization strategy [47] Question: What are the expectations for capital expenditures moving forward? - The company expects capital expenditures to trend at or above 4% of revenues, with a focus on investing in ambulatory build-out [93] Question: How does the company view the impact of the recent Medicare OPPS and ASC rule changes? - Management believes that the shift from inpatient to outpatient care has been ongoing and does not expect a significant influx of patients moving from inpatient to outpatient settings due to clinical acuity needs [99] Question: Can you provide details on the Medicaid supplemental programs and their future? - Management expressed confidence that approved programs in New Mexico and Oklahoma will qualify for grandfathering provisions under the OBBA, ensuring their durability [90][91]

Financial Performance - Total revenue for 2Q25 was $1645 million, an increase of 11.9% year-over-year[14, 18] - Adjusted EBITDA for 2Q25 was $170 million, a 38.9% increase year-over-year[14, 18] - Adjusted EBITDA margin for 2Q25 was 10.3%, a 200 bps expansion[14, 18] - For the first half of 2025, total revenue reached $3143 million, reflecting an 8.0% year-over-year growth[14] - Adjusted EBITDA for YTD 2Q25 was $268 million, up 22.9% year-over-year[14] - Adjusted EBITDA margin for YTD 2Q25 was 8.5%, a 100 bps increase[14] Operating Metrics - Admissions increased by 6.6% year-over-year in 2Q25[14, 26] - Adjusted admissions increased by 1.6% year-over-year in 2Q25 and 2.2% year-to-date[14, 16, 22] - Net patient service revenue per adjusted admission increased by 10.2% year-over-year[14, 25, 27] Payor Mix - Managed Care accounted for 44.7% of Net Patient Service Revenue in 2Q25, an increase of 80 bps year-over-year[29, 30] - Medicare accounted for 40.0% of Net Patient Service Revenue in 2Q25[29, 32] - Medicaid accounted for 10.7% of Net Patient Service Revenue in 2Q25[29, 33]

Rural Healthcare Crisis - Rural healthcare faces a crisis due to potential cuts and closures [1][2] - Texas children, especially those outside major cities, risk losing healthcare access due to Medicaid cuts affecting 30-40% of children [1] - Many Texas counties lack hospitals equipped for childbirth, posing risks for pregnant individuals in emergencies [3] Impact of Policy - A policy is projected to shut down over 300 rural hospitals nationwide [2] - East Texas families may need to travel 45 minutes to an hour to reach a hospital [2] - Rural hospitals struggle to remain open, facing challenges exacerbated by government actions [3] Government Responsibility - The government's role is to provide services to its citizens, not to generate profit [4] - The government is failing to provide services to working-class people [4] - Resources meant for public services are being redirected to wealthy individuals [4]

Group 1 - The core viewpoint of the news is the recognition of Binzhou Medical College Affiliated Hospital as one of the "Top 100 International Science and Technology Cooperation Institutions" by the China International Science and Technology Cooperation Association, highlighting its significant contributions to international scientific collaboration [2] - The hospital has established close ties with institutions in countries such as the United States, Australia, Singapore, and the United Kingdom, focusing on personnel exchanges and academic collaborations [2] - Over the years, the hospital has successfully recruited a lifetime professor from a global Top 200 university and has engaged in academic exchanges with renowned institutions like Harvard Medical School and the University Medical Center Groningen [2] Group 2 - The recognition serves as both an acknowledgment of the hospital's long-term commitment to international scientific cooperation and a result of its diligent efforts in this field [3] - The hospital plans to leverage this recognition to enhance its international talent exchange and cooperation, establishing regular collaborative mechanisms with high-level overseas universities and research institutions [3] - The focus will be on enriching the forms of overseas talent exchange and cooperation, which is expected to empower the hospital's high-quality development [3]

Financial Data and Key Metrics Changes - In Q2 2025, total revenue declined by 3.6%, with EBITDA and net profit decreasing by 1.6% and 3.8% respectively [27][28][33] - The EBITDA margin for Q2 was 41.6%, while the net profit margin was 30.4% [27][33] - For the first half of 2025, total revenue was down 4.6%, with a 5.3% decline in hospital operation revenue [30][33] Business Line Data and Key Metrics Changes - Revenue from non-Thai patients decreased by 6.6%, while Thai patient revenue slightly declined by 0.2% [27][30] - The outpatient service revenue contribution increased to 51% in the first half of 2025, up from 49% in the same period last year [31] - The government third-party contribution dropped to 14% from 18% in the first half of last year due to lower Middle East revenue [31] Market Data and Key Metrics Changes - Middle Eastern business showed strong growth, with Qatar up 18%, UAE up 46%, Oman up 28%, and Saudi Arabia up 54% [6][7] - The company experienced a decline in revenue from the Indo-China segment, particularly from Cambodia, which was offset by growth in Myanmar and Bangladesh [29][30] - The Chinese market saw a significant reduction in patient arrivals, down by over 30% to 40% year over year due to safety concerns [65][66] Company Strategy and Development Direction - The company is focusing on expanding its cancer care services and enhancing patient experience through new facilities and advanced technologies [88][92] - There is an emphasis on strengthening relationships with key stakeholders and third-party payers to drive growth [84] - The company aims to improve its market position by addressing governance issues and enhancing service quality for Kuwaiti patients [42][56] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for Q3 2025, expecting stronger performance compared to the first half of the year [18][26] - The company is cautiously optimistic about the return of Kuwaiti patients and the resolution of past payment issues [46][56] - Management highlighted the importance of addressing safety concerns to regain Chinese patient trust and increase medical tourism [66][70] Other Important Information - The company achieved recognition as one of the best specialized hospitals in Thailand across multiple specialties [77][78] - A successful disease screening campaign generated nearly 96 million baht in revenue within two months [80] - The company is actively investing excess cash into financial assets to capture higher interest income [34][35] Q&A Session Summary Question: What are the expectations for the Kuwaiti market? - Management indicated that discussions with Kuwaiti officials are ongoing, and there is cautious optimism about future collaborations and patient flow [46][56] Question: How is the company addressing the decline in Chinese patient arrivals? - The company is expanding its presence in China and engaging in targeted outreach to rebuild trust and increase referrals [66][70] Question: What are the key initiatives for cancer care expansion? - The company is focusing on comprehensive cancer care, integrating advanced technologies, and enhancing patient experience through new facilities [88][92]

Financial Data and Key Metrics Changes - The total revenue for Q2 2025 was 6,000 million baht, representing a decline of 3.6% year-over-year [26][27] - EBITDA margin reached a record high of 41.6%, while net profit margin was 30.4%, slightly up from 30.5% in the previous year [9][33] - EPS was reported at 40 baht, with a dividend payout ratio of 44% for the interim dividend, up from 41% the previous year [13] Business Line Data and Key Metrics Changes - Revenue from non-Thai patients decreased by 6.6%, while Thai patient revenue slightly declined by 0.2% [26][28] - The outpatient service revenue contribution increased to 51% from 49% in the first half of the previous year, while inpatient service revenue remained at 50% [31] - The MDA segment saw a significant decline of 12.4%, primarily from Qatar, Kuwait, and Oman, while the Indo-China segment increased by 0.4% [29][30] Market Data and Key Metrics Changes - Middle Eastern business showed strong growth, with Qatar up 18%, UAE up 46%, Oman up 28%, and Saudi Arabia up 54% [5][6] - The company experienced a decline in revenue from Chinese patients, with a drop of over 30% to 40% year-over-year due to safety concerns [65] - The Cambodian market is expected to stabilize, which could improve OPD footfalls and admissions in the future [66] Company Strategy and Development Direction - The company is focusing on expanding its cancer care services, recognizing the growing global cancer crisis and the need for comprehensive care [89][90] - Plans for a new cancer care facility are underway, aimed at enhancing patient experience and integrating advanced technologies [95] - The company is actively negotiating with the Kuwaiti government regarding patient payments and potential future collaborations [39][46] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for Q3 2025, expecting stronger performance compared to the first half of the year [16][25] - The company is cautiously optimistic about the return of Kuwaiti patients, emphasizing the importance of quality care and governance [46][60] - The geopolitical situation in Cambodia and China is impacting patient flow, but management is hopeful for recovery in these markets [66][70] Other Important Information - The company received recognition from Newsweek as one of the best specialized hospitals in Thailand, ranking number one in six out of nine specialties [79] - A successful disease screening campaign generated nearly 96 million baht in revenue within two months [82] - The company upgraded its robotic surgery capabilities, expanding to more specialties and training additional surgeons [84] Q&A Session Summary Question: What is the outlook for the Kuwaiti market? - Management indicated that discussions with Kuwaiti officials are ongoing, and there is cautious optimism about future patient flow and payments [39][46] Question: How is the company addressing the decline in Chinese patients? - The company is expanding its presence in China and engaging in online outreach to improve connections with potential patients [67][68] Question: What are the expectations for the second half of 2025? - Management expects stronger performance in the second half compared to the first half, driven by recovery in key markets [16][25]

Financial Performance - Bumrungrad Hospital Public Company Limited's total revenues decreased by 3.6% in 2Q25 compared to 2Q24 and decreased by 4.6% in 1H25 compared to 1H24 [26, 27] - Net profit also experienced a decrease of 3.8% in 2Q25 compared to 2Q24 and a decrease of 8.3% in 1H25 compared to 1H24 [26, 36] - The EBITDA margin reached a company record of 41.6% in 2Q25 [5, 26, 34] - Non-Thai patient revenue decreased by 6.6% in 2Q25 and 8.2% in 1H25 compared to the same periods in the previous year [14, 21, 46, 50] Revenue Analysis - Middle East market share revenue increased by 23% compared to Q1 2025, with notable growth in Qatar (18%), UAE (46%), Oman (28%), and Saudi Arabia (54%) [5] - Non-Thai revenue has shown a CAGR of +5.8% from Y2018 to Y2024 [7] - Middle East non-Thai revenue increased by 56.2% from Y2018 to Y2024, while non-Middle East non-Thai revenue increased by 31.7% during the same period [10] - Inpatient and outpatient services contributed roughly equally to revenues, with inpatient services accounting for 50% in 2Q25 and 49% in 1H25 [29] Business Updates and Developments - Bumrungrad International Hospital has been recognized in Newsweek's Best Specialized Hospitals Asia Pacific 2025 ranking across all 9 specialty fields [52] - The hospital has been approved for renewal of its Advanced Hospital Accreditation (Advanced HA) under the Hospital and Healthcare Standards, with a certification period from May 23, 2025 – May 22, 2029 [55, 56] - A new Bumrungrad Comprehensive Cancer Center is under development, expected to be completed in 2027, with the aim of expanding capacity and enhancing patient experience [78, 80, 105]

Workplace Dynamics - Eight nurses at Lehigh Valley Hospital were pregnant within a few months of each other, fostering a unique bond [2] - The nurses, known as "PGO Floats," use a group chat for support and advice [3] - The group provided support for a nurse undergoing infertility treatments [3][4] - The nurses found the support invaluable during hospital shifts and the uncertainties of pregnancy [5] Human Resources & Employee Well-being - The hospital environment fostered a supportive community among colleagues [5] - The nurses plan to continue supporting each other through motherhood [6]

Core Points - FOXO Technologies Inc. announced that Big South Fork Medical Center has completed a Performance Network Agreement with Covenant Health to provide swing bed services [1][3] - The agreement aims to enhance post-acute care for patients who no longer meet acute care admission criteria, allowing them to recover closer to home [2][3] - The CEO of Big South Fork Medical Center emphasized the hospital's strategic location and service quality as key factors in attracting patients [3] Company Overview - FOXO Technologies Inc. operates three subsidiaries, including Rennova Community Health, which owns Big South Fork Medical Center, a critical access designated hospital [4] - Myrtle Recovery Centers, another subsidiary, provides behavioral health services, including inpatient detox and outpatient treatment programs [4] - FOXO Labs, Inc. focuses on biotechnology aimed at improving human health and lifespan through innovative technology [5]